NEW YORK, NY -- (Marketwired) -- 04/07/14 --
During trial, a new MRI-guided prostate biopsy yielded more targeted prostate tissue retrieval and improved diagnosis accuracy. The combined multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR) guided biopsy (MRGB) techniques reduced the incidence of low-risk prostate cancer diagnosis and improved overall detection of intermediate- to high-risk disease compared to the traditional biopsy method.
Currently, transrectal ultrasound is used to guide the collection of as many as 30 random prostate tissue samples. In contrast, the two-part biopsy uses mpMRI to visually assess the prostate and then, if necessary, MRGB to collect just two needle samples from the tumor-identified area. Leading robotic prostate surgeon, David B. Samadi, MD, believes the new test will improve the patient experience and, more importantly, prostate cancer diagnosis and treatment planning.
"The MRI biopsy gives us the opportunity for very targeted tissue sampling, a more comfortable patient, and more accurate results," said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital.
Based on findings from the Australian clinical trial, researchers believe the mpMRI will better serve men with prostate cancer by increasing the detection of intermediate-risk and high-risk disease. At the same time, men as a whole will benefit from a reduction in over testing and over diagnosis of low-risk, indolent cancer.
From July 2012 through January 2013, a total of 223 men with elevated prostate-specific antigen (PSA) levels participated in the biopsy study. All patients received the mpMRI biopsy and the traditional ultrasound-guided biopsy.
Findings showed three main benefits of mpMRI/MRGB over ultrasound biopsy:
- 51 percent reduction in patient need for prostate biopsy
- 89.4 percent reduction in low-risk prostate cancer diagnosis
- 17.7 percent increased detection of intermediate/high-risk prostate cancer
"While overtreatment of prostate cancer is not ideal, the new test will require us to remain vigilant -- not all low-risk diagnoses can be ignored," said Dr. Samadi. "Patients must work closely with prostate cancer experts to determine the best course of treatment. Individual assessment of risk factors will continue to play a role in the decision about whether or not to undergo treatment, even for those with low-risk diagnosis."
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2561529
Add to Digg
Bookmark with del.icio.us
Add to Newsvine
David B. Samadi, M.D.
Chairman of Urology
Chief of Robotic Surgery at Lenox Hill Hospital
485 Madison Avenue
New York, NY 10022